These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23662843)

  • 1. Fabry disease: is there a role for enzyme replacement therapy?
    Mehta AB
    J Intern Med; 2013 Oct; 274(4):329-30. PubMed ID: 23662843
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.
    Weidemann F; Niemann M; Störk S; Breunig F; Beer M; Sommer C; Herrmann S; Ertl G; Wanner C
    J Intern Med; 2013 Oct; 274(4):331-41. PubMed ID: 23586858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease: dose matters.
    Warnock DG; Mauer M
    J Am Soc Nephrol; 2014 Apr; 25(4):653-5. PubMed ID: 24556355
    [No Abstract]   [Full Text] [Related]  

  • 5. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
    Martin-Suárez I; Suárez-Marrero C
    Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
    [No Abstract]   [Full Text] [Related]  

  • 6. Stroke and Chronic Kidney Disease in Fabry Disease.
    Tapia D; Kimonis V
    J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy for Fabry's disease.
    Waldek S; Germain DP; Wanner C; Warnock DG
    Lancet; 2010 May; 375(9725):1523; author reply 1523-4. PubMed ID: 20435225
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnosis and management of kidney involvement in Fabry disease.
    Warnock DG; West ML
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy for Fabry's disease.
    Deegan P
    Lancet; 2010 May; 375(9725):1522-3; author reply 1523-4. PubMed ID: 20435224
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
    Lenders M; Brand E
    J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
    Lidove O; Choukroun G; Bekri S; Viot G; Tsimaratos M; Joly D
    Presse Med; 2010 May; 39(5):527-9. PubMed ID: 20194001
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
    Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
    [No Abstract]   [Full Text] [Related]  

  • 14. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
    Senocak Tasci E; Bicik Z
    Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undiagnosed Fabry disease: the importance of screening for Fabry disease before transcutaneous patent foramen ovale closure in a young patient with cryptogenic stroke.
    Chimenti C; Alfarano M; Galea N; Verardo R; Grande C; Frustaci A
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):711-713. PubMed ID: 32251074
    [No Abstract]   [Full Text] [Related]  

  • 16. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
    Frustaci A; Russo MA; Chimenti C
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzyme replacement in Fabry disease: the essence is in the kidney.
    Schiffmann R
    Ann Intern Med; 2007 Jan; 146(2):142-4. PubMed ID: 17179053
    [No Abstract]   [Full Text] [Related]  

  • 18. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
    Basic-Jukic N; Kes P; Mokos I; Coric M
    Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
    Linthorst GE; Aerts JM
    J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.